About Probable UDP-sugar transporter protein SLC35A4
Probable UDP-sugar transporter protein SLC35A4 (SLC35A4) is a protein
from Homo sapiens identified by UniProt accession
Q96G79, 324 residues long.
MolForge cross-references it against 0 known binders and
12 disease associations.
Target properties
| Protein name | Probable UDP-sugar transporter protein SLC35A4 |
|---|
| UniProt accession | Q96G79 |
|---|
| Gene | SLC35A4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 324 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (12)
Diseases linked to this target (Open Targets).
- white matter microstructure measurement · score 0.07
- blood protein measurement · score 0.04
- total blood protein measurement · score 0.04
- white matter integrity · score 0.04
- body height · score 0.03
- aspartate aminotransferase measurement · score 0.03
- neoplasm · score 0.01
- hyperinsulinemic hypoglycemia, familial, 4 · score 0.00
- Parkinson disease · score 0.00
- Cognitive impairment · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96G79-F1 | alphafold | PREDICTED | 84.37 | — |
Amino-acid sequence (324 residues)
MSVEDGGMPG LGRPRQARWT LMLLLSTAMY GAHAPLLALC HVDGRVPFRP SSAVLLTELT KLLLCAFSLL VGWQAWPQGP PPWRQAAPFA LSALLYGANN NLVIYLQRYM DPSTYQVLSN LKIGSTAVLY CLCLRHRLSV RQGLALLLLM AAGACYAAGG LQVPGNTLPS PPPAAAASPM PLHITPLGLL LLILYCLISG LSSVYTELLM KRQRLPLALQ NLFLYTFGVL LNLGLHAGGG SGPGLLEGFS GWAALVVLSQ ALNGLLMSAV MKHGSSITRL FVVSCSLVVN AVLSAVLLRL QLTAAFFLAT LLIGLAMRLY YGSR
Explore Probable UDP-sugar transporter protein SLC35A4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets